Immune Checkpoint Inhibitor Efficacy for MSI/dMMR Advanced Pancreatic Ductal Adenocarcinoma
A retrospective analysis found that immune checkpoint inhibitors may be effective and well tolerated in patients with microsatellite instability-high (MSI) or mismatch repair-deficient (dMMR) advanced pancreatic ductal adenocarcinoma.
Data from 31 patients with MSI/dMMR advanced pancreatic ductal adenocarcinoma who were treated with immune checkpoint inhibitors was retrospectively collected from 16 centers. Of the patients, 25 received single-agent anti-PD-1 antibodies, 3 received combination nivolumab-ipilimumab, and 3 received immunotherapy and chemotherapy. This study reports on the objective response rate and disease control rate.
The objective response rate of all patients was 48.4%, with 3 complete responses and 12 partial. Additionally, there were 6 patients with stable disease. The median progression-free survival was 26.7 months, and the median overall survival was not reached. For the 17 patients who had received only 1 line of prior therapy, the disease control rate was 76.5%.
The study authors stated their work “supports the use of PD-1 inhibition in this group of patients with high unmet medical need.”
Source:
Taïeb J, Sayah L, Heinrich K, et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An Association des Gastro-Enterologue Oncologues European Cohort. Eur J Cancer. Published April 22, 2023. doi:10.1016/j.ejca.2023.04.012
